The national drug pricing regulator National Pharmaceutical Pricing Authority (NPPA) has fixed/revised ceiling prices of 45 scheduled formulations of Schedule-I under Drugs (Price Control) Amendment Order, 2016 and Retail Price of 11 formulations under DPCO, 2013 as per notification dated 10.11.2016.

Name of the 45 scheduled formulations for which ceiling prices have been revised are pralidoxime chloride (2 - PAM) injection, efavirenz tablet, imatinib capsule, folic acid capsule, benzoyl peroxide cream, clomiphene capsule, acetazolamide capsule, salbutamol capsule, paracetamol oral liquid, pheniramine injection, naloxone injection, lorazepam injection, phenytoin injection, ceftazidime powder for injection, artesunate + (sulphadoxine+ pyrimethamine) tablet, metoclopramide oral liquid, streptokinase injection, povidone iodine solution, betamethasone cream, tropicamide eye drop, cetrimide solution, mannitol injection, ranitidine injection, dicyclomine injection, ciprofloxacin ointment, gentamicin drops, pilocarpine drops, timolol drops, atropine drops, homatropine drops, hydrocortisone injection, rifampicin tablet, fluconazole capsule, efavirenz capsule, ritonavir capsule, paracetamol suppository, paracetamol suppository, paracetamol oral liquid and carboxymethylcellulose drops.

Name of the 11 scheduled formulations for which retail prices have been revised are teneligliptin + metformin HCl tablet (Tenlimac M 1000), teneligliptin + metformin HCl (SR)tablet, teneligliptin + metformin HCl (ER) tablet, diclofenac sodium + paracetamol tablet, r -H u erythropoietin injection and voglibose + metformin HCl (SR) tablet.

Retail price is applicable only to the individual manufacturers/marketeers i.e. who have applied for the same by submitting Form-I for price fixation/revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the government under relevant statutes/rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.

The concerned manufacturers of these formulations shall furnish quarterly return to the NPPA, in respect of production/import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and/or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

In case the retail price of any of the formulations is not complied with, as per instant price notification and notes specified, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.

Consequent to the issue of retail price of the formulations as specified in this notification, the price order(s) if any, issued for concerned manufacturer/marketeer prior to said date of notification, stand(s) superseded.